IDiyas

For the Inventor, By the Inventor

Barcelona, Spain

Ramon Merce-Vidal

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 74(Granted Patents)


Location History:

  • Marques de Sentmenat, ES (1995)
  • Barcelone, ES (2001 - 2002)
  • Barcelona, ES (1993 - 2012)

Company Filing History:

goldMedal14 out of 150 
 
Laboratorios Del Dr. Esteve S.a.
 patents
silverMedal3 out of 23 
 
Laboratories Del Dr. Esteve S.a.
 patents
bronzeMedal1 out of 1 
 
Laboratories Del Sr. Esteve, S.a.
 patent

Years Active: 1993-2012

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents
1. 8217041 - Indene derivatives, their preparation and use as medicaments (2012-07-10),
2. 8138210 - Substituted indanyl sulfonamide compounds, their preparation and use as medicaments (2012-03-20),
3. 7964603 - Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments (2011-06-21),
4. 7129361 - Thienylazolylalkoxyethanamines, their preparation and their application as medicaments (2006-10-31),
5. RE39113 - Utilization of derivatives of tetrahydropyridines(or 4-hydroxypiperidines)-butylazols in the preparation of a medicament for the treatment of pain (2006-05-29),
6. 6410582 - Thienylazolylalcoxyethanamines, their preparation and their application as medicaments (2002-06-25),
7. 6384055 - Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of a medicament for the treatment of pain (2002-05-07),
8. 6355659 - 4-(4-Chlorophenyl)-1236-tetrahydro-1(1H-124-triazol-1-yl)butty)pyrideine and salts thereof; pharmaceutical compositions and method of treating psychoses utilizing same (2002-03-12),
9. 6346620 - Methods for preparation of 2-(4-(4-(4,5-dichloro-2-methylimidazol-1-yl)butyl)-1-piperazinyl)-5-fluoropyrimidine and salts thereof (2002-02-12),
10. 6303608 - 2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluoropyrimidine, its preparation and its therapeutic use (2001-10-16),
11. 6232329 - Tetrahydropyridine-(or 4-hydroxypiperidine) alkylazoles (2001-05-15),
12. 5731331 - Tetrahydropyridine-(or 4-hydroxypiperidine) alkylazoles (1998-03-24),
13. 5536836 - Process for the preparation of (1996-07-16),
14. 5532234 - Use of 1-[4-[4-aryl (or heteroaryl)-1-piperazinyl]-butyl)-1H-azole (1996-07-02),
15. 5444059 - 2-(4-azolylbutyl)-1-piperazinyl)-5-hydroxy-pyrimidine derivatives, their (1995-08-22),

Title: Ramon Merce-Vidal: Innovator in Medicinal Chemistry

Introduction

Ramon Merce-Vidal is a prominent inventor based in Barcelona, Spain. He has made significant contributions to the field of medicinal chemistry, holding a total of 18 patents. His work primarily focuses on the development of new compounds that have therapeutic applications.

Latest Patents

Among his latest patents, Ramon has developed indene derivatives, which are noted for their preparation and use as medicaments. These new indene derivatives exhibit a general formula (I) and demonstrate affinity for 5-HT receptors, making them effective in treating diseases mediated by these receptors. Another notable patent involves substituted indanyl sulfonamide compounds, which also have a general formula (I). These compounds are prepared for medicinal use and show similar affinity for 5-HT receptors, indicating their potential in therapeutic applications.

Career Highlights

Ramon has worked with notable companies such as Laboratorios del Dr. Esteve S.A. His experience in these organizations has allowed him to refine his expertise in pharmaceutical development and innovation.

Collaborations

Ramon has collaborated with several professionals in his field, including Jordi Frigola-Constansa and Juan Pares-Corominas. These collaborations have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Ramon Merce-Vidal is a distinguished inventor whose work in medicinal chemistry has led to the creation of innovative compounds with significant therapeutic potential. His contributions continue to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…